IPP Bureau
Caplin Steriles receives USFDA final approval for ANDA Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
By IPP Bureau - February 27, 2025
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure
Senores Pharmaceuticals begins operations at greenfield API facility
By IPP Bureau - February 27, 2025
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
By IPP Bureau - February 27, 2025
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Glenmark Pharmaceuticals USA launches Epinephrine Injection USP
By IPP Bureau - February 27, 2025
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report
By IPP Bureau - February 26, 2025
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Merck unveils formulation and technology center in Navi Mumbai
By IPP Bureau - February 26, 2025
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
Cadila Pharmaceuticals opens advanced pharmaceutical warehouse
By IPP Bureau - February 26, 2025
FDA grants EUA to Aptitude’s Covid/flu multiplex test for OTC use
By IPP Bureau - February 26, 2025
Amgen opens new technology and innovation site in Hyderabad
By IPP Bureau - February 25, 2025
Amgen India investment totals $200 million through 2025
Biocon Biologics launches Yesintek Biosimilar to Stelara in US
By IPP Bureau - February 25, 2025
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Indegene launches AI platform Cortex
By IPP Bureau - February 25, 2025
This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
Teva and Sanofi present new outcome from Phase 2b study of duvakitug
By IPP Bureau - February 25, 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
.JPG "Somaiya Vidyavihar University hosts conference on ‘Clinical Translation of Biomaterials for Future Healthcare’")
Briefs: Syngene International and Cipla
By IPP Bureau - February 23, 2025
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences
By IPP Bureau - February 23, 2025
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
